Download or read book Fast Facts Treatment Optimization of Motor Fluctuations in Parkinson s Disease written by Fabrizio Stocchi and published by Karger Medical and Scientific Publishers. This book was released on 2019-06-07 with total page 50 pages. Available in PDF, EPUB and Kindle. Book excerpt: Although dopaminergic medication is the most effective treatment for patients with Parkinson’s disease (PD), its long-term use is associated with debilitating motor fluctuations. Patients may not spontaneously seek assistance when fluctuations develop, so strategies need to be put in place to identify and alleviate motor dysfunction. This concise resource will increase readers’ awareness of: • the different types of motor fluctuation, why they occur and how to recognize them • the drugs that can be added to levodopa to reduce fluctuations • advanced and emerging therapies that will help to improve outcomes. No two patients with PD are alike in their disease progression or response to treatment. This 'Fast Facts' title provides the information healthcare professionals need to provide effective individualized care that will improve their patients’ quality of life.
Download or read book Non Motor Symptoms of Parkinson s Disease written by K. Ray Chaudhuri and published by Oxford University Press, USA. This book was released on 2014 with total page 517 pages. Available in PDF, EPUB and Kindle. Book excerpt: Patients with Parkinson's disease (PD) are known to suffer from motor symptoms of the disease, but they also experience non-motor symptoms (NMS) that are often present before diagnosis or that inevitably emerge with disease progression. The motor symptoms of Parkinson's disease have been extensively researched, and effective clinical tools for their assessment and treatment have been developed and are readily available. In contrast, researchers have only recently begun to focus on the NMS of Parkinson's Disease, which are poorly recognized and inadequately treated by clinicians. The NMS of PD have a significant impact on patient quality of life and mortality and include neuropsychiatric, sleep-related, autonomic, gastrointestinal, and sensory symptoms. While some NMS can be improved with currently available treatments, others may be more refractory and will require research into novel (non-dopaminergic) drug therapies for the future. Edited by members of the UK Parkinson's Disease Non-Motor Group (PD-NMG) and with contributions from international experts, this new edition summarizes the current understanding of NMS symptoms in Parkinson's disease and points the way towards future research.
Download or read book Parkinson s Disease written by National Collaborating Centre for Chronic Conditions (Great Britain) and published by Royal College of Physicians. This book was released on 2006 with total page 243 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Parkinson s Disease Current and Future Therapeutics and Clinical Trials written by Néstor Gálvez-Jiménez and published by Cambridge University Press. This book was released on 2016-03-24 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book emphasizes treatment options for Parkinson's disease, providing the necessary clinical and scientific basis for the foundations of solid therapeutics.
Download or read book Levodopa pharmacokinetics from stomach to brain written by Maria Nord and published by Linköping University Electronic Press. This book was released on 2019-01-07 with total page 81 pages. Available in PDF, EPUB and Kindle. Book excerpt: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Download or read book Parkinson s Disease Management through ICT written by Joan Cabestany and published by CRC Press. This book was released on 2022-09-01 with total page 166 pages. Available in PDF, EPUB and Kindle. Book excerpt: Parkinson's Disease (PD) is a neurodegenerative disorder that manifests with motor and non-motor symptoms. PD treatment is symptomatic and tries to alleviate the associated symptoms through an adjustment of the medication. As the disease is evolving and this evolution is patient specific, it could be very difficult to properly manage the disease.The current available technology (electronics, communication, computing, etc.), correctly combined with wearables, can be of great use for obtaining and processing useful information for both clinicians and patients allowing them to become actively involved in their condition.Parkinson's Disease Management through ICT: The REMPARK Approach presents the work done, main results and conclusions of the REMPARK project (2011 – 2015) funded by the European Union under contract FP7-ICT-2011-7-287677. REMPARK system was proposed and developed as a real Personal Health Device for the Remote and Autonomous Management of Parkinson’s Disease, composed of different levels of interaction with the patient, clinician and carers, and integrating a set of interconnected sub-systems: sensor, auditory cueing, Smartphone and server. The sensor subsystem, using embedded algorithmics, is able to detect the motor symptoms associated with PD in real time. This information, sent through the Smartphone to the REMPARK server, is used for an efficient management of the disease.
Download or read book Deep Brain Stimulation Management written by William J. Marks, Jr and published by Cambridge University Press. This book was released on 2015-09-03 with total page 251 pages. Available in PDF, EPUB and Kindle. Book excerpt: Essential reference guide for clinicians working with DBS patients, fully revised throughout with new chapters on epilepsy and psychiatric disorders.
Download or read book Non motor Parkinson s Disease written by Néstor Gálvez-Jiménez and published by Cambridge University Press. This book was released on 2022-03-10 with total page 271 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive and practical manual describing the manifestations, pathophysiology and treatments for non-motor Parkinson's Disease. Topics covered in depth include autonomic and sexual dysfunction, mood disorders, sleep disturbances and drug-induced non-motor symptoms.
Download or read book Rehabilitation in Movement Disorders written by Robert Iansek and published by Cambridge University Press. This book was released on 2013-05-23 with total page 263 pages. Available in PDF, EPUB and Kindle. Book excerpt: Provides a broad overview of current rehabilitation approaches, emphasizing the need for interdisciplinary management and focussing on deliverable outcomes.
Download or read book Parkinson s Disease written by Sten-Magnus Aquilonius and published by . This book was released on 2012 with total page 255 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Clinical Trials In Parkinson s Disease written by Santiago Perez-Lloret and published by Humana. This book was released on 2020-08-19 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume looks at major clinical trials for motor and non-motor symptoms in Parkinson’s Disease (PD) and covers important aspects, including trial design, sample selection, and outcome selection. Chapters in this book discuss topics such as toxin-based rodent or genetic models of PD; clinical trials for motor symptoms, L-DOPA related motor complications, and gait disorders; clinical trials for mood disorders, troubled sleep, autonomic dysfunction; and clinical trials for disease modifying therapies. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory or research center. Cutting-edge and authoritative, Clinical Trials in Parkinson’s Disease is a valuable resource for clinicians and researchers who want to enhance their interpretation of results from clinical trials and to design their own high-quality trials.
Download or read book Cerebro cerebellar Interactions written by J. Massion and published by Elsevier-North-Holland Biomedical Press. This book was released on 1979 with total page 1280 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book International Neurology written by Robert P. Lisak and published by John Wiley & Sons. This book was released on 2016-04-13 with total page 776 pages. Available in PDF, EPUB and Kindle. Book excerpt: This unique textbook deals with the variations in the causes, presentations and treatment of neurological disease throughout human populations. International Neurology is an indispensable guide to the full range of neurological conditions you will see in your ever-changing patient population. Comprehensive coverage of neurological diseases and disorders with a clinical approach to diagnosis, treatment and management Truly international authorship distils expert knowledge from around the world Succinct, bite-sized, templated chapters allow for rapid clinical referral Further reading recommendations for each chapter guide readers requiring more depth of information Endorsed by the World Federation of Neurology
Download or read book Leucine Rich Repeat Kinase 2 LRRK2 written by Hardy J. Rideout and published by Springer. This book was released on 2017-03-28 with total page 280 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is the first book to assemble the leading researchers in the field of LRRK2 biology and neurology and provide a snapshot of the current state of knowledge, encompassing all major aspects of its function and dysfunction. The contributors are experts in cell biology and physiology, neurobiology, and medicinal chemistry, bringing a multidisciplinary perspective on the gene and its role in disease. The book covers the identification of LRRK2 as a major contributor to the pathogenesis of Parkinson's Disease. It also discusses the current state of the field after a decade of research, putative normal physiological roles of LRRK2, and the various pathways that have been identified in the search for the mechanism(s) of its induction of neurodegeneration.
Download or read book Autonomic Dysfunction in Parkinson s Disease written by Cristian Falup-Pecurariu and published by Academic Press. This book was released on 2021-09-28 with total page 316 pages. Available in PDF, EPUB and Kindle. Book excerpt: Autonomic dysfunction is one of the most prevalent non-motor symptoms that occurs in Parkinson's disease. Autonomic Dysfunction in Parkinson's Disease provides up to date information on this important topic, which affects quality of life of these patients. This include a large number of domains: orthostatic hypotension, excessive sweating, dry eyes, constipation, weight loss, increased sensitivity to heat and cold, sexual dysfunction. - Provides comprehensive reviews on different topics of autonomic dysfunction in Parkinson's disease - Each chapter covers a specific autonomic symptom: classification, assessment, treatment - Presents the newest information on each autonomic symptom in Parkinson's disease
Download or read book Atypical Parkinsonian Disorders written by Irene Litvan and published by Springer Science & Business Media. This book was released on 2007-10-27 with total page 515 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive review of what is known not only about the cause and treatment of atypical parksonian disorders, but also the issues that clinicians, researchers, patients, and caregivers face in dealing with them. The authors cover the basic science (history, epidemiology, genetics, pathology, nosology, computer modeling, and animal models), detailed clinical and laboratory assessments, and available diagnostic tools, including neuropsychiatric, neurologic, neuropsychologic, speech, electrophysiologic, and imaging evaluations. Current and future therapeutic approaches are also detailed, along with extensive discussions about future research directions.
Download or read book Cyclin Dependent Kinase 5 Cdk5 written by Nancy Y. Ip and published by Springer Science & Business Media. This book was released on 2009-02-28 with total page 326 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cyclin Dependent Kinase 5 provides a comprehensive and up-to-date collection of reviews on the discovery, signaling mechanisms and functions of Cdk5, as well as the potential implication of Cdk5 in the treatment of neurodegenerative diseases. Since the identification of this unique member of the Cdk family, Cdk5 has emerged as one of the most important signal transduction mediators in the development, maintenance and fine-tuning of neuronal functions and networking. Further studies have revealed that Cdk5 is also associated with the regulation of neuronal survival during both developmental stages and in neurodegenerative diseases. These observations indicate that precise control of Cdk5 is essential for the regulation of neuronal survival. The pivotal role Cdk5 appears to play in both the regulation of neuronal survival and synaptic functions thus raises the interesting possibility that Cdk5 inhibitors may serve as therapeutic treatment for a number of neurodegenerative diseases.
